Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein
- PMID: 12396618
- DOI: 10.1089/104303402760372954
Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein
Abstract
Gene transfer of p53 induces cell death in most cancer cells, and replication-defective adenoviral vectors expressing p53 are being evaluated in clinical trials. However, low transduction efficiency limits the efficacy of replication-defective vector systems for cancer therapy. The use of replication-competent vectors for gene delivery may have several advantages, holding the potential to multiply and spread the therapeutic agent after infection of only a few cells. However, expression of a transgene may adversely affect viral replication. We have constructed a replicating adenoviral vector (Adp53rc) that expresses high levels of p53 at a late time point in the viral life cycle and also contains a deletion of the adenoviral death protein (ADP). Adp53rc-infected cancer cells demonstrated high levels of p53 expression in parallel with the late expression pattern of the adenoviral fiber protein. p53 expression late in the viral life cycle did not impair effective virus propagation. Survival of several lung cancer cell lines was significantly diminished after infection with Adp53rc, compared with an identical p53-negative control virus. p53 expression also improved virus release and spread. Interestingly, p53 was more cytotoxic than the ADP in cancer cells but less cytotoxic than the ADP in normal cells. In conclusion, late expression of p53 from a replicating virus improves tumor cell killing and viral spread without impairing viral replication. In addition, in combination with a deletion of the ADP, specificity of tumor cell killing is improved.
Similar articles
-
Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.Cancer Res. 2001 Dec 15;61(24):8743-50. Cancer Res. 2001. PMID: 11751394
-
High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.Cancer Gene Ther. 1994 Mar;1(1):5-13. Cancer Gene Ther. 1994. PMID: 7621238
-
Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene.Hum Gene Ther. 1999 Mar 1;10(4):579-90. doi: 10.1089/10430349950018652. Hum Gene Ther. 1999. PMID: 10094201
-
Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.Curr Opin Mol Ther. 1999 Aug;1(4):500-9. Curr Opin Mol Ther. 1999. PMID: 11713766 Review.
-
Improving adenoviral vectors and strategies for prostate cancer gene therapy.Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e476s. doi: 10.6061/clinics/2018/e476s. Clinics (Sao Paulo). 2018. PMID: 30133562 Free PMC article. Review.
Cited by
-
Adenoviral protein V promotes a process of viral assembly through nucleophosmin 1.Virology. 2012 Oct 25;432(2):283-95. doi: 10.1016/j.virol.2012.05.028. Epub 2012 Jun 18. Virology. 2012. PMID: 22717133 Free PMC article.
-
Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter.Cancer Gene Ther. 2006 Jul;13(7):720-3. doi: 10.1038/sj.cgt.7700944. Epub 2006 Feb 17. Cancer Gene Ther. 2006. PMID: 16485010 Free PMC article.
-
Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.Gene Ther. 2008 Sep;15(17):1240-5. doi: 10.1038/gt.2008.94. Epub 2008 May 29. Gene Ther. 2008. PMID: 18509378 Free PMC article.
-
Adeno-associated virus enhances wild-type and oncolytic adenovirus spread.Hum Gene Ther Methods. 2013 Dec;24(6):372-80. doi: 10.1089/hgtb.2013.124. Epub 2013 Oct 8. Hum Gene Ther Methods. 2013. PMID: 24020980 Free PMC article.
-
Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.Cancer Gene Ther. 2021 Aug;28(7-8):745-756. doi: 10.1038/s41417-020-0192-9. Epub 2020 Jul 1. Cancer Gene Ther. 2021. PMID: 32606392 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous